We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 21, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Gilead Sciences Inc. (GILD - Free Report) , Legend Biotech Corp. (LEGN - Free Report) , BeiGene Ltd. (BGNE - Free Report) , Exact Sciences Corp. (EXAS - Free Report) and Sarepta Therapeutics Inc. (SRPT - Free Report) .
Here are highlights from Monday’s Analyst Blog:
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Things are looking better for the biotech industry in the second half of 2023 after a decent performance in the first half as the world cautiously wades through an uncertain macroeconomic environment.
Next year is likely to bring more cheer for the industry as most market participants think the Fed is already through with its ongoing interest rate hike cycle and the first rate cut may take place in the first half of 2024.
The majority of the biotech players do not generate enough revenues to fund their operations and are dependent on external funds. A company starts generating revenues following a successful FDA approval and launch of any drug.
Under this circumstance, a low interest rate environment is likely to raise the margins of biotech players as these companies need a huge amount of capital to continue clinical studies before getting an FDA approval.
With the pandemic behind us, biotech companies are looking to bolster their product portfolios and pipeline through collaborations and buyouts. Hence, mergers and acquisitions are back in the spotlight.
Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry can be a safe haven despite the inherent volatility and uncertain macroeconomic environment.
An attractive pipeline candidate is the key lure for biotech companies. Cost synergies in research and development (R&D) are added benefits, as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. With increasing R&D spend and most companies looking to diversify, new drug approvals are likely to see an acceleration going forward.
Our Top Picks
We have narrowed our search to five biotech stocks with strong potential for 2024. These stocks have seen positiveLEGN, BGNE, earnings estimate revisions in the last 30 days. Each of our picks carries a Zacks Rank #2 (Buy). You can seethe complete list of today's Zacks #1 Rank (Strong BUY) stocks here.
Gilead Sciences Inc. maintains momentum as growth in the flagship HIV therapy, Biktarvy, remains strong. GILD's oncology revenues are driven by its cell therapy franchise and Trodelvy. Solid growth from Yescarta and Tecartus and the label expansion of Trodelvy will further boost GILD's oncology franchise.
GILD's efforts to solidify its oncology franchise through internal pipeline development and strategic collaborations have broadened its pipeline. The successful development of differentiated oncology drugs holds the key for GILD.
Gilead Sciences has an expected revenue and earnings growth rate of 1.9% and 10.4%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 0.7% over the last seven days.
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, and is engaged in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
LEGN's lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma. LEGN also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
Legend Biotech has an expected revenue and earnings growth rate of 86.6% and 50.3%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 6.9% over the last seven days.
BeiGene Ltd. develops and commercializes oncology medicines worldwide. BGNE's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BGNE has collaborations with several large biotech companies.
BeiGene has an expected revenue and earnings growth rate of 21.7% and 15.5%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 2% over the last seven days.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. EXAS has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. EXAS is also working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics.
Exact Sciences has an expected revenue and earnings growth rate of 12.9% and 17.1%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 6.2% over the last 30 days.
Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focusing on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. SRPT concentrates on the development of exon-skipping drug candidates targeting DMD, a rare genetic disorder affecting children (primarily males). DMD is the most common type of muscular dystrophy.
SRPT received accelerated approval for its DMD drug, Exondys 51 (eteplirsen), in the United States as a once-weekly intravenous infusion in 2016, specifically targeting patients who have a confirmed mutation of the DMD gene susceptible to exon 51 skipping.
Sarepta Therapeutics has an expected revenue and earnings growth rate of 44.6% and 106.1%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved more than 100% over the last 30 days.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
For Immediate Release
Chicago, IL – November 21, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Gilead Sciences Inc. (GILD - Free Report) , Legend Biotech Corp. (LEGN - Free Report) , BeiGene Ltd. (BGNE - Free Report) , Exact Sciences Corp. (EXAS - Free Report) and Sarepta Therapeutics Inc. (SRPT - Free Report) .
Here are highlights from Monday’s Analyst Blog:
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Things are looking better for the biotech industry in the second half of 2023 after a decent performance in the first half as the world cautiously wades through an uncertain macroeconomic environment.
Next year is likely to bring more cheer for the industry as most market participants think the Fed is already through with its ongoing interest rate hike cycle and the first rate cut may take place in the first half of 2024.
The majority of the biotech players do not generate enough revenues to fund their operations and are dependent on external funds. A company starts generating revenues following a successful FDA approval and launch of any drug.
Under this circumstance, a low interest rate environment is likely to raise the margins of biotech players as these companies need a huge amount of capital to continue clinical studies before getting an FDA approval.
With the pandemic behind us, biotech companies are looking to bolster their product portfolios and pipeline through collaborations and buyouts. Hence, mergers and acquisitions are back in the spotlight.
Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry can be a safe haven despite the inherent volatility and uncertain macroeconomic environment.
An attractive pipeline candidate is the key lure for biotech companies. Cost synergies in research and development (R&D) are added benefits, as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. With increasing R&D spend and most companies looking to diversify, new drug approvals are likely to see an acceleration going forward.
Our Top Picks
We have narrowed our search to five biotech stocks with strong potential for 2024. These stocks have seen positiveLEGN, BGNE, earnings estimate revisions in the last 30 days. Each of our picks carries a Zacks Rank #2 (Buy). You can seethe complete list of today's Zacks #1 Rank (Strong BUY) stocks here.
Gilead Sciences Inc. maintains momentum as growth in the flagship HIV therapy, Biktarvy, remains strong. GILD's oncology revenues are driven by its cell therapy franchise and Trodelvy. Solid growth from Yescarta and Tecartus and the label expansion of Trodelvy will further boost GILD's oncology franchise.
GILD's efforts to solidify its oncology franchise through internal pipeline development and strategic collaborations have broadened its pipeline. The successful development of differentiated oncology drugs holds the key for GILD.
Gilead Sciences has an expected revenue and earnings growth rate of 1.9% and 10.4%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 0.7% over the last seven days.
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, and is engaged in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
LEGN's lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma. LEGN also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
Legend Biotech has an expected revenue and earnings growth rate of 86.6% and 50.3%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 6.9% over the last seven days.
BeiGene Ltd. develops and commercializes oncology medicines worldwide. BGNE's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BGNE has collaborations with several large biotech companies.
BeiGene has an expected revenue and earnings growth rate of 21.7% and 15.5%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 2% over the last seven days.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. EXAS has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. EXAS is also working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics.
Exact Sciences has an expected revenue and earnings growth rate of 12.9% and 17.1%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved 6.2% over the last 30 days.
Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focusing on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. SRPT concentrates on the development of exon-skipping drug candidates targeting DMD, a rare genetic disorder affecting children (primarily males). DMD is the most common type of muscular dystrophy.
SRPT received accelerated approval for its DMD drug, Exondys 51 (eteplirsen), in the United States as a once-weekly intravenous infusion in 2016, specifically targeting patients who have a confirmed mutation of the DMD gene susceptible to exon 51 skipping.
Sarepta Therapeutics has an expected revenue and earnings growth rate of 44.6% and 106.1%, respectively, for next year. The Zacks Consensus Estimate for next-year earnings has improved more than 100% over the last 30 days.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.